A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma

In conclusion, cisplatin plus epirubicin appears as an effective regimen in malignant mesothelioma, with a favourable toxicity profile. However, it does not demonstrate superior activity to other active regimens in this disease.